FDA Refines Forms to Monitor Doctors' Drug Trial Finances
Published Date: 5/1/2025
Notice
Summary
The FDA wants to keep better track of clinical investigators by updating their financial disclosure forms. This affects doctors and researchers who test new medicines and devices, making sure they’re honest about money ties. The government is asking for approval to collect this info, aiming to keep things fair without costing extra time or money.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Updated Financial Disclosures for Investigators
The FDA is proposing updated financial disclosure forms to better track clinical investigators — the doctors and researchers who test new medicines and devices. The proposed collection was submitted to the Office of Management and Budget for review under the Paperwork Reduction Act, and the agency says it aims to keep things fair without costing extra time or money.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
Previous / Next Documents
Previous: 2025-07576, Importer of Controlled Substances Application: United States Pharmacopeial Convention
The United States Pharmacopeial Convention wants to officially import certain controlled substances. This affects anyone tracking drug imports and ensures these substances are handled safely and legally. Keep an eye out for updates on their registration status and any related rules or fees.
Next: 2025-07578, Agency Information Collection Activities; Proposed Collection; Comment Request; Compounding Animal Drugs From Bulk Drug Substances
The FDA wants your thoughts on how vets and drug makers keep records when mixing animal medicines from bulk ingredients. This helps make sure animal drugs are safe and made right. You’ve got 60 days to share your ideas—no cost changes, just a chance to improve the rules!